C-C趋化因子配体5及其受体C-C趋化因子配体5辅助受体在胃癌中的研究进展
Research progress in C-C chemokine ligand 5 and chemokine C-C motif receptor 5 in gastric cancer
尹清玲 1谢雪晴 1田菁菁 2卢伟 2侯美君 2陈训盛 2曾丽丽 2刘槟 2朱远琳 2张科 2丁杰2
作者信息
- 1. 贵州大学医学院,贵州 550025
- 2. 贵州省人民医院胃肠外科,贵州 550002
- 折叠
摘要
胃癌是一种常见的恶性肿瘤,其患者晚期预后差,5年生存率低于50％,其发病机制目前尚未清楚.肿瘤微环境(TME)的存在促进了肿瘤细胞增殖、迁移能力及免疫逃逸能力,进而促进肿瘤的发生发展.C-C趋化因子配体5(CCL5)是TME中的一种趋化因子,CCL5与其受体C-C趋化因子配体5辅助受体(CCR5)组成的生物轴在招募肿瘤相关免疫抑制细胞中发挥着积极的作用,已有研究表明该轴与胃癌细胞的生长和转移密切相关.因此,CCL5/CCR5生物轴有望在胃癌的诊断、治疗以及预后方面提供更多依据和指导.本文回顾了 CCL5/CCR5生物轴在胃癌发生及发展过程中的作用及相关靶向治疗的研究进展.
Abstract
Gastric cancer is a common malignant tumor with poor prognosis and 5-year survival rate of less than 50％.Its pathogenesis is still unclear.The existence of tumor microenvironment(TME)promoted the proliferation,migration and immune escape ability of tumor cells,thus promoting the occurrence and development of tumors.C-C chemokine ligand 5(CCL5)is a chemokine in the TME.The biological axis composed of CCL5 and its receptor,che-mokine C-C motif receptor 5(CCR5),plays an active role in the recruitment of tumor-associated immunosuppressive cells,and has been shown to be closely related to the growth and metastasis of gastric cancer cells.Therefore,the CCL5/CCR5 biological axis is expected to provide more evidence and guidance in the diagnosis,treatment and progno-sis of gastric cancer.This article reviews the role of CCL5/CCR5 biological axis in the occurrence and development of gastric cancer and the progress of related targeted therapy.
关键词
胃癌/趋化因子配体/肿瘤微环境Key words
Gastric cancer/Chemokine ligand/Tumor microenvironment引用本文复制引用
基金项目
国家自然科学基金(81360366)
国家自然科学基金(81302169)
国家自然科学基金(82360586)
贵州省科技计划(黔科合基础[2019]1198)
贵州省科技计划(黔科合基础[2020]1Z064)
出版年
2024
NETL
NSTL
万方数据